The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer  

作　　者：Kun Li Bo Yang Yingying Du Yi Ding Shihui Shen Zhengwang Sun Yun Liu Yuhan Wang Siyuan Cao Wenjie Ren Xiangyu Wang Mengjuan Li Yunpeng Zhang Juan Wu Wei Zheng Wangjun Yan Lei Li 

机构地区：[1]Department of Musculoskeletal Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,China [2]Health Science Center,East China Normal University,Shanghai 200241,China [3]Chongqing Key Laboratory of Precision Optics,Chongqing Institute of East China Normal University,Chongqing 401120,China [4]School of Life Sciences,East China Normal University,Shanghai 200241,China [5]Joint Center for Translational Medicine,Shanghai Fifth People’s Hospital,Fudan University and School of Life Science,East China Normal University,Shanghai 200240,China [6]Department of Pharmacy The General Hospital of Western Theater Command,Chengdu 610083,China [7]Orthopaedic Department of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai 200233,China [8]Department of Orthopedics,General Hospital of Western Theater Command,Chengdu 610000,China [9]College of Medicine,Southwest Jiaotong University,Chengdu 610031,P.R.China

出　　处：《Bone Research》2024年第3期704-719,共16页骨研究（英文版）

基　　金：sponsored by National Natural Science Foundation of China (82303396,82022051,82072972 and 81672883);Science and Technology Commission of Shanghai (22YF1408400);Shanghai Pilot Program for Basic Research (TQ20240208);Natural Science Foundation of Chongqing (CSTB2024NSCQ-JQX0009 and CSTB2024NSCQ-MSX0594);The Postdoctoral Foundation of China (2023T160122);Anti-cancer Association in Shanghai,Joint Foundation from Fudan University Shanghai Cancer Center (YJQN202102);Science&Techenology Department of Sichuan Province (2023NSFSC0705);the Fund of major military joint research project (2019LH 02);Shanghai municipal hospital emerging frontier joint research project (SHDC12024112)。

摘　　要：While KRAS mutation is the leading cause of low survival rates in lung cancer bone metastasis patients,effective treatments are still lacking.Here,we identified homeobox C10(HOXC10)as a lynchpin in pan-KRAS-mutant lung cancer bone metastasis.

关 键 词：METASTASIS NOD1 HOX 

分 类 号：R734.2[医药卫生—肿瘤]